Myovant Sciences, part of a constellation of biotech startups, said Tuesday that its treatment for uterine fibroids succeeded in the first of two large trials, a major step toward winning approval.

The drug, relugolix, met its goal of significantly reducing menstrual blood loss over 24 weeks and beat placebo on six other metrics including pain and quality of life. In the roughly 400-patient trial, relugolix was similar to placebo, including on the key measure of bone density.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy